Report of Foreign Issuer (6-k)
August 26 2016 - 4:41PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August, 2016
Commission
File Number: 001-37423
Biotie
Therapies Oyj
(Exact
name of registrant as specified in its charter)
Biotie
Therapies Corp.
(Translation
of registrant’s name into English)
Joukahaisenkatu
6, FI-20520
Turku,
Finland
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
BIOTIE THERAPIES CORP.
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Kristian Rantala
|
|
|
|
|
|
Name:
|
Kristian Rantala
|
|
|
|
|
|
Title:
|
Chief Financial Officer
|
Date:
August 26, 2016
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
Stock
Exchange Release dated August 26, 2016 (2:30 p.m. EET): BTT1023 receives Orphan Drug Designation in the United
States
|